ArticlePhysiological research2026
Glucagon-Like Peptide-2 Ameliorates Lipid Metabolism in Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Adiponectin-Adiponectin Receptor-Mediated AMPK/PPARalpha Pathway.
Article in Physiological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trilobatin is associated with reduced lipid accumulation in multiple biological models: insights from transcriptomics, molecular docking, and molecular dynamics simulations.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to investigate the mechanisms by which glucagon-like peptide-2 (GLP-2) improves metabolic dysfunction-associated steatotic liver disease (MASLD) induced by free fatty acids (FFAs) in HepG2 cells, with a focus on the regulation of the adiponectin (ADPN) signaling axis and the downstream AMP-activated protein kinase (AMPK)/peroxisome proliferator-activated receptor alpha (PPARalpha) pathway. An MASLD model was established in HepG2 cells by FFA exposure. Following GLP-2 treatment, improvements in lipid metabolism were evaluated using the Cell Counting Kit-8, Oil Red O staining, and biochemical assays. Differential gene expression was examined using RNA sequencing, and potential mechanisms were evaluated through Gene Ontology enrichment and Kyoto Encyclopedia of Genes and Genomes pathway analysis. Western blotting and reverse transcription polymerase chain reaction (RT-PCR) were performed to assess the expression of key molecular components within the signaling pathway. FFA treatment led to significant lipid accumulation in HepG2 cells, whereas GLP-2 reduced intracellular lipid droplet formation (p<0.01) and decreased triglyceride and total cholesterol levels in a dose-dependent manner (p<0.05). KEGG enrichment analysis indicated that GLP-2 acted on the adipokine, AMPK, and PPARalpha pathways. Western blotting and RT-PCR confirmed that GLP-2 restored protein expression (p<0.01) and mRNA expression (p<0.05) of adiponectin receptor 1, adiponectin receptor 2, and downstream signaling molecules AMPK and PPARalpha in FFA-treated HepG2 cells. GLP-2 alleviated FFA-induced hepatocyte steatosis by modulating the AMPK/PPARalpha pathway through the regulation of ADPN and its receptors. These findings provide a theoretical foundation for the potential use of gut hormones in the treatment of MASLD. Keywords Adiponectin " AMPK " Glucagon-like peptide-2 " Metabolic dysfunction-associated steatotic liver disease " PPARalpha.
Indexed as
Identifiers
41811706PMC13127996What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.